Clinical Approach to Weakness
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of weakness
Weakness is one of the most common and challenging presenting complaints in primary care, accounting for approximately 5-10% of all ambulatory visits. Studies show that “weakness” or “fatigue” ranks among the top 10 reasons for physician encounters, with an estimated 20-30 million visits annually in the United States alone. The diagnostic challenge lies in the fact that patients use the term “weakness” to describe a wide spectrum of experiences — from true loss of muscle strength to fatigue, malaise, or even psychological distress.
Definition
True weakness (paresis) refers to a measurable reduction in muscle strength — the inability to generate normal force against resistance. This must be distinguished from fatigue (a subjective sense of exhaustion or lack of energy), exercise intolerance (inability to sustain effort), and asthenia (generalized lack of strength without objective weakness). This distinction is the critical first step in evaluating any patient presenting with “weakness.”
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Less than 4 weeks | Stroke, Guillain-Barré syndrome, spinal cord compression, electrolyte disturbances, acute myopathy | Often represents neurological emergency; requires urgent evaluation to prevent irreversible damage |
| Subacute | 4 weeks to 3 months | Inflammatory myopathies, subacute combined degeneration, paraneoplastic syndromes, thyroid disorders | Suggests inflammatory, metabolic, or early degenerative processes; workup should be thorough but less urgent |
| Chronic | Greater than 3 months | Muscular dystrophies, motor neuron disease, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis | Often progressive neuromuscular conditions; focus on establishing diagnosis and functional optimization |
Classification by Character
True Weakness versus Fatigue
True weakness: Patient cannot perform a specific motor task even with maximal effort (e.g., cannot lift arm above head, cannot rise from chair). Objective and reproducible on examination.
Fatigue: Patient can perform the task initially but strength diminishes with repetition or over time. Often associated with systemic illness, depression, or deconditioning.
Generalized versus Focal
Generalized weakness: Affects multiple muscle groups diffusely. Suggests systemic causes (metabolic, endocrine, inflammatory) or diffuse neuromuscular disease.
Focal weakness: Limited to specific muscles, limbs, or body regions. Strongly suggests structural neurological lesion — localization is key to diagnosis.
Proximal versus Distal
Proximal weakness: Affects shoulder girdle and hip muscles preferentially. Classic for myopathies (difficulty rising from chairs, climbing stairs, brushing hair).
Distal weakness: Affects hands and feet first. Typical of peripheral neuropathies (difficulty with fine motor tasks, foot drop).
Symmetric versus Asymmetric
Symmetric weakness: Affects both sides equally. Suggests metabolic, toxic, or hereditary causes.
Asymmetric weakness: One side affected more than the other. Raises concern for stroke, radiculopathy, mononeuropathy, or focal lesion.
Classification by Pattern and Timing
| Pattern | Description | Suggests |
|---|---|---|
| Sudden onset (seconds to minutes) | Weakness develops abruptly, often with clear time of onset | Vascular event (stroke, spinal cord infarction), trauma, seizure with Todd’s paralysis |
| Rapidly progressive (hours to days) | Weakness evolves quickly over short period | Guillain-Barré syndrome, transverse myelitis, myasthenic crisis, acute inflammatory myopathy |
| Slowly progressive (weeks to months) | Gradual worsening over extended period | Motor neuron disease, muscular dystrophy, chronic inflammatory demyelinating polyneuropathy, malignancy |
| Fluctuating | Weakness varies throughout day or with activity | Myasthenia gravis (worse with use, better with rest), periodic paralysis, multiple sclerosis |
| Episodic | Discrete attacks of weakness with normal intervals | Periodic paralysis, transient ischemic attack, metabolic myopathies |
| Static | Weakness present but not progressing | Prior stroke, old polio, congenital myopathy, stable neuropathy |
Key Concept: The Localization Imperative
The most important task in evaluating weakness is anatomical localization. Ask yourself: Is the lesion in the upper motor neuron (brain or spinal cord), lower motor neuron (anterior horn cell, nerve root, peripheral nerve), neuromuscular junction, or muscle itself? The pattern of weakness, associated findings (reflexes, sensory changes, fasciculations), and tempo of onset will guide you to the correct level — and this determines the entire diagnostic and management pathway.
Clinical Impact
Why This Matters
Weakness significantly impacts quality of life, functional independence, and mortality. Progressive weakness can lead to falls, aspiration pneumonia, respiratory failure, and loss of independence. Early recognition of serious causes (such as Guillain-Barré syndrome, myasthenic crisis, or spinal cord compression) can be life-saving. Conversely, many patients presenting with “weakness” have treatable causes (electrolyte abnormalities, medication effects, thyroid disease) that can be completely reversed with appropriate intervention.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of weakness
Voluntary muscle contraction requires an intact motor pathway extending from the cerebral cortex to the muscle fiber. Weakness results when any component of this pathway is disrupted. Understanding the anatomy of the motor system is essential for localizing the lesion and directing appropriate investigation.
The Motor Pathway
| Component | Structure | Function |
|---|---|---|
| Upper Motor Neuron | Motor cortex → corticospinal tract → spinal cord | Initiates and modulates voluntary movement; provides descending control to lower motor neurons |
| Lower Motor Neuron | Anterior horn cell → nerve root → peripheral nerve | Final common pathway; directly innervates muscle fibers; conducts action potential to muscle |
| Neuromuscular Junction | Motor nerve terminal → synaptic cleft → muscle endplate | Converts electrical signal to chemical (acetylcholine release) then back to electrical (muscle depolarization) |
| Muscle Fiber | Sarcolemma → T-tubules → sarcoplasmic reticulum → myofibrils | Excitation-contraction coupling; actin-myosin cross-bridge cycling generates force |
Localization by Level of Lesion
Upper Motor Neuron
Location: Brain (cortex, internal capsule, brainstem) or spinal cord
Pattern: Weakness in pyramidal distribution (extensors in arms, flexors in legs); affects whole limb or hemibody
Associated signs: Increased tone (spasticity), hyperreflexia, positive Babinski sign, no atrophy (initially), no fasciculations
Lower Motor Neuron
Location: Anterior horn cell, nerve root, plexus, or peripheral nerve
Pattern: Weakness in myotomal (root) or peripheral nerve distribution; can be focal or diffuse
Associated signs: Decreased tone (flaccidity), hyporeflexia or areflexia, muscle atrophy, fasciculations, sensory loss (if nerve involved)
Neuromuscular Junction
Location: Presynaptic terminal or postsynaptic membrane
Pattern: Fluctuating weakness; fatigable; often affects ocular, bulbar, and proximal limb muscles
Associated signs: Normal reflexes (until severe), no sensory loss, no atrophy (early), ptosis and diplopia common
Myopathy (Muscle Disease)
Location: Muscle fiber itself (structural or metabolic defect)
Pattern: Proximal and symmetric weakness; affects shoulder and hip girdle muscles preferentially
Associated signs: Normal or reduced reflexes (proportional to weakness), no sensory loss, atrophy (variable), myalgia may be present, elevated creatine kinase
Systemic/Metabolic Causes
Location: Diffuse effect on muscle or nerve function
Pattern: Generalized weakness, often with fatigue predominant; may be episodic
Associated signs: Signs of underlying condition (thyroid abnormalities, Cushingoid features, dehydration); laboratory abnormalities
How Specific Conditions Cause Weakness
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Stroke | Ischemic or hemorrhagic damage to upper motor neurons in cortex or corticospinal tract; sudden loss of descending motor control | Time-critical intervention (thrombolysis, thrombectomy); rehabilitation for recovery |
| Guillain-Barré syndrome | Autoimmune demyelination of peripheral nerves following infection; antibodies attack myelin or axons; conduction block | Immunotherapy (intravenous immunoglobulin or plasmapheresis); monitor respiratory function |
| Myasthenia gravis | Autoantibodies block acetylcholine receptors at neuromuscular junction; reduced endplate potential; fatigable weakness | Acetylcholinesterase inhibitors; immunosuppression; thymectomy in selected patients |
| Inflammatory myopathy (polymyositis, dermatomyositis) | T-cell or antibody-mediated destruction of muscle fibers; inflammatory infiltrate causes fiber necrosis | Corticosteroids and steroid-sparing immunosuppressants; screen for malignancy |
| Hypokalemia | Potassium essential for muscle membrane repolarization; low levels cause hyperpolarization and reduced excitability | Potassium replacement; identify and treat underlying cause (diuretics, gastrointestinal losses) |
| Hypothyroidism | Reduced thyroid hormone impairs muscle metabolism and protein synthesis; causes myopathy and slowed relaxation | Thyroid hormone replacement; weakness resolves over weeks to months |
| Amyotrophic lateral sclerosis | Progressive degeneration of both upper and lower motor neurons; mechanism incompletely understood; excitotoxicity and protein aggregation implicated | Supportive care; riluzole may modestly slow progression; multidisciplinary management |
| Spinal cord compression | Mechanical compression disrupts corticospinal tracts; can affect both upper motor neurons (below lesion) and lower motor neurons (at lesion level) | Urgent imaging and decompression; corticosteroids for malignant compression |
| Statin-induced myopathy | Statins deplete coenzyme Q10 and alter muscle membrane cholesterol; mitochondrial dysfunction; can range from myalgia to rhabdomyolysis | Discontinue statin; consider alternative lipid-lowering therapy; most cases reversible |
Often Overlooked Mechanism: The “Split” Pattern in Amyotrophic Lateral Sclerosis
In amyotrophic lateral sclerosis (ALS), the combination of upper and lower motor neuron signs is the diagnostic hallmark. A valuable clinical clue is the “split hand” — preferential wasting of the thenar muscles (abductor pollicis brevis) and first dorsal interosseous compared to the hypothenar muscles. This asymmetric atrophy within the same hand is relatively specific for ALS and reflects the disease’s predilection for certain motor neuron pools. Recognizing this pattern can prompt earlier diagnosis in patients presenting with hand weakness.
Complications of Weakness Itself
| Complication | Mechanism | Prevention/Management |
|---|---|---|
| Respiratory failure | Weakness of diaphragm and intercostal muscles reduces vital capacity; inability to cough leads to atelectasis and pneumonia | Monitor forced vital capacity; early ventilatory support; aggressive pulmonary toilet |
| Aspiration pneumonia | Bulbar weakness impairs swallowing and airway protection; silent aspiration common | Swallowing assessment; modified diet consistency; consider feeding tube if severe |
| Falls and fractures | Lower extremity and truncal weakness impair balance and mobility | Physical therapy; assistive devices; fall risk assessment; bone health optimization |
| Deep vein thrombosis | Immobility from weakness leads to venous stasis | Prophylactic anticoagulation in hospitalized patients; early mobilization |
| Contractures | Prolonged immobility and muscle imbalance lead to soft tissue shortening | Range of motion exercises; splinting; physical therapy |
3. History Taking
A comprehensive approach to eliciting the weakness history
Red Flags — Require Urgent Evaluation
- Sudden onset weakness — Stroke, spinal cord infarction
- Rapidly ascending weakness — Guillain-Barré syndrome
- Respiratory distress or dyspnea — Neuromuscular respiratory failure
- Dysphagia or dysarthria — Bulbar involvement, myasthenic crisis
- Bladder or bowel dysfunction — Spinal cord compression, cauda equina syndrome
- Neck or back pain with weakness — Spinal cord or root compression
- Fever with weakness — Infectious myelitis, epidural abscess, sepsis
- Ptosis with diplopia — Myasthenia gravis, botulism
- Known malignancy with new weakness — Metastatic cord compression, paraneoplastic syndrome
- Recent trauma with weakness — Spinal cord injury, nerve injury
Systematic History: The “WEAKNESS” Approach
Use the mnemonic “WEAKNESS” to ensure comprehensive history taking:
- W — What exactly do you mean?: Clarify if patient means true weakness, fatigue, or something else. Ask: “Can you not do something you used to be able to do, or do you feel tired and worn out?”
- E — Evolution and onset: When did it start? Sudden (seconds), rapid (hours-days), or gradual (weeks-months)? Stable, progressive, or fluctuating?
- A — Anatomical distribution: Which muscles are affected? Proximal or distal? Symmetric or asymmetric? Face, arms, legs, or trunk?
- K — Key associated symptoms: Sensory changes? Pain? Cramps? Fasciculations? Diplopia? Dysphagia? Breathing difficulty? Bladder/bowel changes?
- N — Neurological and medical history: Prior neurological disease? Autoimmune conditions? Thyroid disease? Diabetes? Malignancy? Recent infections?
- E — Exacerbating and relieving factors: Worse with activity (myasthenia)? Better with rest? Worse at end of day? Triggered by cold or heat?
- S — Social and occupational history: Alcohol use? Toxic exposures? Occupation? Recent travel? Diet and nutrition?
- S — Substances and medications: Statins? Steroids? Chemotherapy? Antiretrovirals? Recreational drugs? Supplements?
Distinguishing True Weakness from Fatigue
| Feature | True Weakness | Fatigue/Asthenia |
|---|---|---|
| Patient description | “I can’t lift my arm” or “My leg gives out” | “I’m exhausted” or “I have no energy” |
| Specific task limitation | Cannot perform specific motor task even with effort | Can perform task but feels exhausted; lacks motivation |
| Objective findings | Measurable reduction in muscle strength on examination | Normal strength on testing; effort may be poor |
| Key question | “Show me what you cannot do” | “Do you feel tired all the time or just lack energy?” |
| Likely causes | Neurological or neuromuscular disease | Depression, chronic disease, sleep disorders, anemia, hypothyroidism |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Stroke or transient ischemic attack | Sudden onset, unilateral, face/arm/leg, speech changes | “Exactly what time did this start? Did it come on all at once or gradually?” |
| Guillain-Barré syndrome | Ascending weakness, areflexia, post-infectious | “Did you have a cold, flu, or diarrhea in the past few weeks? Did the weakness start in your feet and move upward?” |
| Myasthenia gravis | Fluctuating weakness, ptosis, diplopia, bulbar symptoms, worse with use | “Is your weakness worse at the end of the day? Do your eyelids droop or do you see double? Is chewing or swallowing difficult?” |
| Inflammatory myopathy | Proximal weakness, myalgia, skin rash (dermatomyositis) | “Do you have trouble climbing stairs or getting up from a chair? Any muscle pain? Any rash on your face, hands, or chest?” |
| Motor neuron disease (amyotrophic lateral sclerosis) | Mixed upper and lower motor neuron signs, fasciculations, bulbar symptoms | “Have you noticed twitching in your muscles? Has your speech changed or do you choke on food? Any cramps?” |
| Spinal cord compression | Weakness below a level, sensory level, sphincter dysfunction | “Do you have back or neck pain? Any numbness below a certain level? Any difficulty with urination or bowel control?” |
| Peripheral neuropathy | Distal weakness, sensory loss, “glove and stocking” distribution | “Did the weakness start in your feet or hands? Do you have numbness or tingling? Do you have diabetes or drink alcohol?” |
| Thyroid disorder | Proximal weakness, weight changes, heat/cold intolerance | “Have you had any weight changes? Do you feel hot or cold when others don’t? Any tremor or palpitations?” |
| Electrolyte disturbance | Generalized weakness, arrhythmia, cramps | “Have you had vomiting, diarrhea, or been taking water pills? Any muscle cramps or palpitations?” |
| Medication-induced myopathy | Proximal weakness, temporal relationship to drug | “When did you start your statin or any new medications? Did the weakness begin after starting a new medicine?” |
Medication and Social History
Medications That Cause Weakness
- Statins (HMG-CoA reductase inhibitors) — Myopathy, rarely rhabdomyolysis; risk increased with high doses, drug interactions, hypothyroidism
- Corticosteroids — Proximal myopathy with chronic use; typically affects hip flexors and shoulder girdle
- Colchicine — Neuromyopathy, especially with renal impairment; can mimic Guillain-Barré syndrome
- Zidovudine and other antiretrovirals — Mitochondrial myopathy with proximal weakness
- Hydroxychloroquine — Slowly progressive vacuolar myopathy; can also cause cardiomyopathy
- Amiodarone — Proximal myopathy and peripheral neuropathy
- Vincristine and other chemotherapeutics — Peripheral neuropathy with distal weakness
- Fluoroquinolones — Tendinopathy and rare myopathy; can exacerbate myasthenia gravis
- Neuromuscular blocking agents — Prolonged weakness in ICU setting (critical illness myopathy/neuropathy)
Social and Occupational History
- Alcohol use: Chronic alcoholism causes myopathy (acute and chronic) and peripheral neuropathy; often with nutritional deficiency
- Occupation: Lead exposure (painters, battery workers) causes motor neuropathy; organophosphates cause neuromuscular weakness
- Diet and nutrition: Vitamin B12 deficiency (vegans, malabsorption) causes subacute combined degeneration; vitamin D deficiency causes myopathy
- Travel: Tick paralysis (ascending flaccid paralysis); polio in endemic areas; tropical infections
- Recent illness: Viral prodrome preceding Guillain-Barré syndrome; Campylobacter gastroenteritis is classic trigger
- Recreational drugs: Cocaine causes rhabdomyolysis; heroin causes compressive neuropathy
- Family history: Muscular dystrophies, hereditary neuropathies (Charcot-Marie-Tooth), periodic paralysis
Assessing Functional Impact
Key Functional Questions
Understanding functional limitations helps gauge severity and monitor progression:
- Proximal arm weakness: “Can you wash and brush your hair? Can you reach items on high shelves?”
- Proximal leg weakness: “Can you rise from a chair without using your arms? Can you climb stairs? Do you use a railing?”
- Distal arm weakness: “Can you open jars? Button your shirt? Turn a key in a lock?”
- Distal leg weakness: “Do you trip over curbs? Does your foot slap when you walk? Do you wear an ankle brace?”
- Respiratory involvement: “Are you short of breath when lying flat? Do you wake up gasping? Can you count to 20 in one breath?”
- Bulbar involvement: “Has your voice changed? Do you choke on liquids? Has food gotten stuck?”
4. Physical Examination
A systematic approach for patients presenting with weakness
Systematic Framework: The neurological examination for weakness follows a “Localization-First” approach. Your goal is to determine whether the lesion is in the upper motor neuron, lower motor neuron, neuromuscular junction, or muscle — and to identify the specific anatomical site. Combine inspection, tone assessment, strength testing, reflexes, and sensory examination to localize precisely.
General Inspection
- Body habitus: Cushingoid features (steroid myopathy); muscle wasting pattern; obesity (obstructive sleep apnea contributing to fatigue)
- Posture and gait: Waddling gait (proximal weakness); foot drop and steppage gait (peroneal neuropathy); spastic gait (upper motor neuron); ataxic gait (cerebellar or sensory)
- Muscle bulk: Atrophy (lower motor neuron, myopathy, disuse); pseudohypertrophy (Duchenne muscular dystrophy); fasciculations at rest
- Skin: Heliotrope rash around eyes, Gottron papules on knuckles (dermatomyositis); butterfly rash (systemic lupus erythematosus); café-au-lait spots (neurofibromatosis)
- Facial appearance: Ptosis (myasthenia, Horner syndrome, third nerve palsy); facial weakness (myopathy, Bell palsy, stroke); expressionless face (myotonic dystrophy)
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Respiratory rate and pattern | Tachypnea, shallow breathing, use of accessory muscles, paradoxical abdominal movement | Neuromuscular respiratory failure; diaphragmatic weakness; impending ventilatory failure |
| Oxygen saturation | Hypoxemia, especially when supine | May be preserved until late in neuromuscular respiratory failure; check arterial blood gas if concerned |
| Heart rate | Tachycardia or bradycardia; irregular rhythm | Autonomic involvement (Guillain-Barré syndrome); electrolyte disturbance (hypokalemia); thyroid disease |
| Blood pressure | Hypertension or labile blood pressure; orthostatic hypotension | Autonomic dysfunction (Guillain-Barré syndrome, diabetic neuropathy); Cushing response (increased intracranial pressure) |
| Temperature | Fever | Infectious cause (epidural abscess, viral myelitis, sepsis); may also reflect aspiration pneumonia as complication |
Critical: Bedside Respiratory Assessment
In any patient with neuromuscular weakness, assess respiratory function at the bedside:
- Single-breath count: Ask patient to take a deep breath and count as high as possible. Normal is greater than 25; less than 15 suggests significant respiratory muscle weakness.
- Forced vital capacity (if available): Less than 20 mL/kg or declining by more than 30% indicates impending respiratory failure.
- Negative inspiratory force: Weaker than -30 cm H2O is concerning; weaker than -20 cm H2O often requires intubation.
- Cough strength: Weak cough indicates inability to clear secretions and increased aspiration risk.
Cranial Nerve Examination
| Cranial Nerve | Test | Abnormal Finding and Significance |
|---|---|---|
| II, III (Pupils) | Pupillary light reflex | Dilated unreactive pupil with ptosis suggests third nerve palsy; small reactive pupil with ptosis suggests Horner syndrome |
| III, IV, VI (Eye movements) | Extraocular movements, sustained upgaze | Diplopia and fatigable ptosis in myasthenia gravis; ophthalmoplegia in Miller Fisher syndrome; internuclear ophthalmoplegia in multiple sclerosis |
| V (Trigeminal) | Jaw clench, facial sensation | Weak jaw clench in myasthenia gravis; sensory loss in trigeminal neuropathy |
| VII (Facial) | Smile, eye closure, forehead raise | Upper motor neuron pattern (forehead spared) versus lower motor neuron pattern (entire face affected); bilateral facial weakness in Guillain-Barré syndrome, myasthenia gravis |
| IX, X (Bulbar) | Palate elevation, gag reflex, voice quality | Nasal speech, palatal weakness, absent gag suggest bulbar palsy; critical in myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome |
| XI (Accessory) | Shoulder shrug, head turn against resistance | Trapezius and sternocleidomastoid weakness; can be affected in amyotrophic lateral sclerosis, accessory nerve palsy |
| XII (Hypoglossal) | Tongue protrusion, inspection for atrophy and fasciculations | Tongue atrophy and fasciculations are lower motor neuron signs (amyotrophic lateral sclerosis); deviation toward weak side |
Motor Examination
Inspection
- Muscle bulk: Compare sides; look for focal atrophy (especially small hand muscles, shoulder girdle, quadriceps)
- Fasciculations: Spontaneous muscle twitching visible under skin; indicates lower motor neuron pathology (amyotrophic lateral sclerosis, radiculopathy)
- Tremor: Resting tremor (Parkinson disease); action tremor (essential tremor, cerebellar disease)
Tone
- Spasticity: Velocity-dependent increase in tone; “clasp-knife” quality; indicates upper motor neuron lesion
- Rigidity: Constant resistance throughout range; “lead-pipe” or “cogwheel” quality; indicates extrapyramidal disease
- Flaccidity: Reduced or absent tone; indicates lower motor neuron lesion, acute upper motor neuron lesion (spinal shock), or myopathy
- Myotonia: Delayed relaxation after contraction; grip myotonia in myotonic dystrophy
Strength Testing (Medical Research Council Scale)
| Grade | Description |
|---|---|
| 5 | Normal strength against full resistance |
| 4 | Movement against gravity and some resistance (4-, 4, 4+ for further gradation) |
| 3 | Movement against gravity but not against resistance |
| 2 | Movement with gravity eliminated |
| 1 | Flicker of contraction, no movement |
| 0 | No contraction |
Key Muscle Groups to Test
Upper Limb
- Shoulder abduction (C5): Deltoid — “Hold your arms out, don’t let me push down”
- Elbow flexion (C5-C6): Biceps — “Bend your elbow, pull me toward you”
- Elbow extension (C7): Triceps — “Straighten your elbow, push me away”
- Wrist extension (C6-C7): Wrist extensors — “Cock your wrist back”
- Finger extension (C7): Finger extensors — “Straighten your fingers”
- Finger abduction (T1): Interossei — “Spread your fingers apart”
- Thumb abduction (T1): Abductor pollicis brevis — “Point your thumb to ceiling”
Lower Limb
- Hip flexion (L1-L2): Iliopsoas — “Lift your leg off the bed”
- Hip extension (L5-S1): Gluteus maximus — “Push your leg down into the bed”
- Knee extension (L3-L4): Quadriceps — “Kick out your leg, don’t let me bend it”
- Knee flexion (L5-S1): Hamstrings — “Bend your knee, pull your heel to your buttock”
- Ankle dorsiflexion (L4-L5): Tibialis anterior — “Pull your foot up toward your shin”
- Ankle plantarflexion (S1-S2): Gastrocnemius — “Push your foot down like a gas pedal”
- Great toe extension (L5): Extensor hallucis longus — “Pull your big toe up”
Reflex Examination
| Reflex | Root Level | Hyperreflexia Suggests | Hyporeflexia/Areflexia Suggests |
|---|---|---|---|
| Biceps | C5-C6 | Upper motor neuron lesion above C5 | C5-C6 radiculopathy, peripheral neuropathy, myopathy (if severe) |
| Triceps | C7 | Upper motor neuron lesion above C7 | C7 radiculopathy, peripheral neuropathy |
| Brachioradialis | C5-C6 | Upper motor neuron lesion above C5 | C5-C6 radiculopathy |
| Knee (patellar) | L3-L4 | Upper motor neuron lesion above L3 | L3-L4 radiculopathy, femoral neuropathy, peripheral neuropathy |
| Ankle (Achilles) | S1 | Upper motor neuron lesion above S1 | S1 radiculopathy, peripheral neuropathy, diabetic neuropathy |
Pathological Reflexes
- Babinski sign (extensor plantar response): Upgoing great toe with fanning of other toes indicates upper motor neuron lesion
- Hoffman sign: Flicking the middle fingernail causes thumb and index finger flexion; suggests cervical cord or upper motor neuron lesion
- Clonus: Sustained rhythmic contractions with rapid dorsiflexion of ankle; indicates upper motor neuron pathology
- Jaw jerk: Brisk jaw jerk indicates upper motor neuron lesion above pons; helpful in localizing amyotrophic lateral sclerosis
Sensory Examination
Why Sensory Examination Matters in Weakness
Sensory findings help localize the lesion and narrow the differential:
- Pure motor weakness (no sensory loss): Motor neuron disease, pure motor neuropathy, myopathy, neuromuscular junction disorder
- Sensory level on trunk: Spinal cord lesion — the level localizes the lesion
- Dermatomal sensory loss: Radiculopathy
- Glove and stocking sensory loss: Peripheral polyneuropathy
- Dissociated sensory loss (loss of pain/temperature with preserved position/vibration or vice versa): Spinal cord lesion (syringomyelia, Brown-Séquard syndrome, subacute combined degeneration)
Functional and Provocative Tests
| Test | How to Perform | What It Tests |
|---|---|---|
| Gower sign | Ask patient to rise from sitting on floor | Positive (using hands to “climb up” legs) indicates proximal weakness — classic for muscular dystrophy |
| Chair rise test | Ask patient to rise from chair without using arms | Difficulty indicates proximal leg weakness (myopathy, polymyositis) |
| Heel and toe walking | Walk on heels, then on toes | Heel walking tests ankle dorsiflexors (L4-L5); toe walking tests plantarflexors (S1) |
| Pronator drift | Arms extended, palms up, eyes closed for 20 seconds | Arm drifts downward and pronates in upper motor neuron weakness; downward without pronation in lower motor neuron or myopathic weakness |
| Sustained upgaze | Ask patient to look up at ceiling for 60-90 seconds | Fatigable ptosis develops in myasthenia gravis |
| Repeated shoulder abduction | Raise arms repeatedly overhead | Progressive weakening with repetition in myasthenia gravis |
| Ice pack test | Apply ice pack to closed eyelid for 2 minutes | Improvement in ptosis suggests myasthenia gravis (cooling improves neuromuscular transmission) |
Expected Findings by Etiology
| Condition | Pattern of Weakness | Tone | Reflexes | Other Key Findings |
|---|---|---|---|---|
| Stroke | Hemiparesis (face, arm, leg) contralateral to lesion | Initially flaccid, then spastic | Hyperreflexia (after acute phase), Babinski positive | Dysarthria, aphasia, visual field cut, hemisensory loss |
| Guillain-Barré syndrome | Ascending, symmetric, proximal and distal | Flaccid | Areflexia (early and prominent) | Facial weakness, autonomic dysfunction, minimal sensory findings |
| Myasthenia gravis | Fatigable; ocular, bulbar, proximal limb | Normal | Normal (preserved) | Ptosis, diplopia, dysarthria, dysphagia; improves with rest |
| Inflammatory myopathy | Proximal, symmetric (hip and shoulder girdle) | Normal or slightly reduced | Normal or reduced proportional to weakness | Muscle tenderness, skin rash in dermatomyositis, dysphagia |
| Amyotrophic lateral sclerosis | Mixed; may start focal then spread | Mixed (spastic and flaccid) | Hyperreflexia with atrophy (pathognomonic) | Fasciculations, tongue atrophy, split hand, bulbar signs, no sensory loss |
| Spinal cord compression | Below the level of lesion; may be asymmetric initially | Spastic (below lesion) | Hyperreflexia below, may have hyporeflexia at level | Sensory level, sphincter dysfunction, back pain |
| Peripheral polyneuropathy | Distal, symmetric, legs greater than arms | Reduced | Hyporeflexia or areflexia (ankles first) | Glove and stocking sensory loss, foot drop |
Important Teaching Point
The combination of signs is the key to localization:
- Upper motor neuron: Weakness + spasticity + hyperreflexia + Babinski = lesion in brain or spinal cord
- Lower motor neuron: Weakness + flaccidity + atrophy + fasciculations + areflexia = lesion in anterior horn, root, or nerve
- Both upper and lower motor neuron signs together: Think motor neuron disease (amyotrophic lateral sclerosis)
- Weakness with normal reflexes and no sensory loss: Think neuromuscular junction (myasthenia gravis) or myopathy
5. Differential Diagnosis
Systematic approach organized by probability, duration, and anatomical localization
Acute Weakness (Less than 4 weeks)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON | Stroke or transient ischemic attack | Sudden onset, unilateral, face-arm-leg pattern, speech changes, vascular risk factors | Sudden onset, altered consciousness, severe headache |
| COMMON | Electrolyte disturbances (hypokalemia, hypercalcemia, hyponatremia) | Generalized weakness, associated with diuretics, vomiting, diarrhea; may have arrhythmias, cramps | Cardiac arrhythmias, respiratory muscle involvement, altered mental status |
| COMMON | Acute deconditioning or critical illness | Generalized weakness after prolonged illness, hospitalization, or bed rest; diffuse and symmetric | Respiratory failure, inability to wean from ventilator |
| LESS COMMON | Guillain-Barré syndrome | Ascending paralysis over days, areflexia, post-infectious (1-4 weeks after respiratory or gastrointestinal illness) | Rapid progression, respiratory involvement, autonomic instability |
| LESS COMMON | Myasthenic crisis | Rapidly worsening weakness in known myasthenia gravis; often triggered by infection, medication, or surgery | Respiratory failure, inability to handle secretions, severe dysphagia |
| LESS COMMON | Spinal cord compression | Weakness below a level, back pain, sensory level, bowel/bladder dysfunction | Rapid progression, sphincter dysfunction, known malignancy |
| LESS COMMON | Transverse myelitis | Bilateral weakness and sensory changes below a level, develops over hours to days, often post-infectious | Rapid progression, respiratory involvement, sphincter dysfunction |
| UNCOMMON BUT SERIOUS | Botulism | Descending paralysis starting with cranial nerves, diplopia, dilated pupils, constipation; history of wound, canned food, or injection drug use | Respiratory failure, bulbar weakness, autonomic dysfunction |
| UNCOMMON BUT SERIOUS | Acute inflammatory myopathy (immune-mediated necrotizing myopathy) | Rapid onset severe proximal weakness, very high creatine kinase (often greater than 10,000 U/L), may be statin-triggered | Rhabdomyolysis, respiratory muscle involvement, dysphagia |
| UNCOMMON BUT SERIOUS | Tick paralysis | Ascending flaccid paralysis, areflexia, exposure to tick-endemic area; rapidly reversible with tick removal | Respiratory failure if unrecognized |
Subacute Weakness (4 weeks to 3 months)
Clinical Approach to Subacute Weakness:
- Step 1: Confirm true weakness versus fatigue — many subacute presentations are actually fatigue from systemic illness
- Step 2: Localize the lesion — Is this upper motor neuron, lower motor neuron, neuromuscular junction, or muscle?
- Step 3: Consider inflammatory, metabolic, and neoplastic causes — these are the most common in this timeframe
| Probability | Condition | Key Distinguishing Features |
|---|---|---|
| COMMON | Inflammatory myopathy (polymyositis, dermatomyositis) | Proximal symmetric weakness, elevated creatine kinase, skin rash in dermatomyositis (heliotrope rash, Gottron papules), dysphagia; may be paraneoplastic |
| COMMON | Thyroid myopathy (hypothyroidism or hyperthyroidism) | Hypothyroid: proximal weakness, delayed relaxation of reflexes, elevated creatine kinase, myalgia. Hyperthyroid: proximal weakness, brisk reflexes, tremor, weight loss |
| COMMON | Medication-induced myopathy (statins, steroids) | Temporal relationship to medication; statins cause proximal weakness and myalgia; steroids cause painless proximal weakness (especially with high doses or prolonged use) |
| LESS COMMON | Myasthenia gravis (new diagnosis) | Fatigable weakness, ptosis, diplopia, bulbar symptoms; worse with activity, better with rest; symptoms fluctuate throughout day |
| LESS COMMON | Subacute combined degeneration (vitamin B12 deficiency) | Combined upper and lower motor neuron signs, sensory ataxia, paresthesias, cognitive changes; macrocytic anemia may or may not be present |
| LESS COMMON | Paraneoplastic syndrome | Subacute cerebellar degeneration, Lambert-Eaton myasthenic syndrome, or sensorimotor neuropathy in setting of occult malignancy (especially small cell lung cancer) |
| UNCOMMON | Inclusion body myositis | Slowly progressive but may present subacutely; distinctive pattern with finger flexor and quadriceps weakness; older males; poor response to immunotherapy |
Chronic Weakness (Greater than 3 months)
| Probability | Condition | Key Distinguishing Features |
|---|---|---|
| COMMON | Chronic inflammatory demyelinating polyneuropathy | Progressive proximal and distal weakness over months, areflexia, sensory involvement, elevated cerebrospinal fluid protein; treatable |
| COMMON | Diabetic polyneuropathy | Distal symmetric sensorimotor neuropathy in diabetic patient; sensory symptoms often precede motor; may have autonomic features |
| COMMON | Cervical or lumbar spondylotic myelopathy/radiculopathy | Myelopathy: spastic gait, upper motor neuron signs in legs, hand clumsiness. Radiculopathy: dermatomal weakness, sensory loss, pain |
| LESS COMMON | Amyotrophic lateral sclerosis (motor neuron disease) | Combined upper and lower motor neuron signs, progressive, fasciculations, no sensory loss; mean survival 3-5 years without intervention |
| LESS COMMON | Muscular dystrophy (limb-girdle, facioscapulohumeral, myotonic) | Pattern depends on type; often hereditary; limb-girdle affects proximal muscles; facioscapulohumeral affects face and scapular fixators; myotonic has grip myotonia |
| LESS COMMON | Multiple sclerosis | Relapsing-remitting or progressive course; dissemination in time and space; may have optic neuritis, sensory symptoms, bladder dysfunction, fatigue |
| UNCOMMON | Hereditary neuropathy (Charcot-Marie-Tooth disease) | Slowly progressive distal weakness and atrophy (especially peroneal muscles), pes cavus, hammer toes, family history; onset in childhood or adolescence |
| UNCOMMON | Spinal muscular atrophy (adult onset) | Progressive lower motor neuron weakness, proximal greater than distal, no sensory involvement; genetic testing diagnostic |
Anatomical Approach to Localization
Upper Motor Neuron (Brain/Spinal Cord)
Stroke
Multiple sclerosis
Spinal cord compression
Transverse myelitis
Cervical spondylotic myelopathy
Brain tumor
Lower Motor Neuron (Anterior Horn to Nerve)
Amyotrophic lateral sclerosis
Spinal muscular atrophy
Radiculopathy
Guillain-Barré syndrome
Chronic inflammatory demyelinating polyneuropathy
Diabetic neuropathy
Neuromuscular Junction
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Botulism
Organophosphate poisoning
Drug-induced (aminoglycosides, magnesium)
Muscle (Myopathy)
Inflammatory myopathy (polymyositis, dermatomyositis)
Muscular dystrophy
Thyroid myopathy
Statin-induced myopathy
Steroid myopathy
Metabolic myopathy
Drug-Induced Weakness
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Statins (HMG-CoA reductase inhibitors) | Mitochondrial dysfunction, coenzyme Q10 depletion, altered membrane cholesterol | Proximal myopathy, myalgia; risk increased with high dose, drug interactions (fibrates, macrolides), hypothyroidism; creatine kinase may be normal or elevated | Weeks to months; immune-mediated necrotizing myopathy may persist |
| Corticosteroids | Protein catabolism, type II fiber atrophy | Proximal weakness (hip flexors affected early), painless, normal creatine kinase; dose and duration dependent | Months; may take 3-6 months for full recovery |
| Colchicine | Disrupts microtubules, causes vacuolar myopathy and axonal neuropathy | Proximal myopathy and sensorimotor neuropathy; elevated creatine kinase; risk increased with renal impairment | Weeks to months |
| Hydroxychloroquine | Vacuolar myopathy from lysosomal accumulation | Slowly progressive proximal weakness; may also cause cardiomyopathy; curvilinear bodies on biopsy | Months to years; may be irreversible |
| Zidovudine and nucleoside analogues | Mitochondrial DNA depletion | Proximal myopathy, myalgia, elevated creatine kinase; “ragged red fibers” on biopsy | Weeks to months |
| Amiodarone | Lysosomal phospholipidosis affecting nerve and muscle | Proximal myopathy and/or sensorimotor neuropathy; may cause tremor | Months (long half-life) |
| Fluoroquinolones | Uncertain; may affect mitochondria; can worsen myasthenia gravis by blocking neuromuscular junction | Tendinopathy more common than myopathy; can precipitate myasthenic crisis | Days to weeks |
| Immune checkpoint inhibitors | Autoimmune myositis or myasthenia as immune-related adverse event | Can cause severe myositis, myasthenia gravis, or overlap syndrome; may be life-threatening | Variable; may require immunosuppression |
| Alcohol (chronic use) | Direct toxic effect on muscle; nutritional deficiency (thiamine, vitamin B12) | Acute rhabdomyolysis or chronic proximal myopathy; often with peripheral neuropathy | Months with abstinence and nutrition |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Sudden hemiparesis with facial droop | Stroke | Emergent CT head; consider thrombolysis/thrombectomy |
| Ascending weakness with areflexia after viral illness | Guillain-Barré syndrome | Admit, monitor respiratory function, lumbar puncture, nerve conduction studies |
| Ptosis and diplopia worse at end of day | Myasthenia gravis | Acetylcholine receptor antibodies, repetitive nerve stimulation, CT chest for thymoma |
| Proximal weakness with heliotrope rash | Dermatomyositis | Creatine kinase, myositis-specific antibodies, MRI muscle, biopsy; screen for malignancy |
| Weakness with fasciculations and brisk reflexes | Amyotrophic lateral sclerosis | Electromyography, nerve conduction studies, MRI brain and spine; exclude mimics |
| Weakness below a level with back pain and sphincter dysfunction | Spinal cord compression | Emergent MRI spine; consider dexamethasone if malignant; urgent surgical consultation |
| Proximal weakness on statin with elevated creatine kinase | Statin-induced myopathy | Stop statin; check creatine kinase trend; if not improving, consider immune-mediated necrotizing myopathy |
| Distal weakness with glove-stocking sensory loss in diabetic | Diabetic polyneuropathy | Nerve conduction studies; optimize glycemic control; evaluate for other causes |
| Descending paralysis with dilated pupils and constipation | Botulism | Stool and serum for botulinum toxin; supportive care; antitoxin |
| Proximal weakness that improves with repeated effort | Lambert-Eaton myasthenic syndrome | Voltage-gated calcium channel antibodies; repetitive nerve stimulation; CT chest for malignancy |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical localization
Baseline Investigations for All Patients with Weakness
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count | Screen for anemia, infection, malignancy | Anemia (may cause fatigue misinterpreted as weakness); macrocytosis (vitamin B12 deficiency); lymphopenia (HIV, autoimmune) | Macrocytic anemia with neurological symptoms warrants urgent B12 level |
| Comprehensive metabolic panel | Electrolytes, renal function, glucose | Hypokalemia, hyperkalemia, hypercalcemia, hyponatremia (all cause weakness); renal failure (uremic myopathy, drug accumulation); hyperglycemia (diabetic neuropathy) | Correct electrolyte abnormalities before extensive workup |
| Creatine kinase (CK) | Detect muscle damage | Elevated in myopathy, rhabdomyolysis, motor neuron disease (mildly); very high (greater than 10,000 U/L) in necrotizing myopathy, rhabdomyolysis | Normal CK does not exclude myopathy (especially steroid myopathy); obtain before electromyography (needle can elevate CK) |
| Thyroid-stimulating hormone (TSH) | Screen for thyroid disease | Hypothyroidism causes proximal myopathy and delayed relaxation of reflexes; hyperthyroidism causes proximal weakness and brisk reflexes | Both hypo- and hyperthyroidism cause weakness; always check |
| Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) | Screen for inflammation | Elevated in inflammatory myopathy, vasculitis, infection, malignancy | Non-specific; normal does not exclude inflammatory disease |
| Vitamin B12 level | Screen for deficiency | Low B12 causes subacute combined degeneration (combined upper and lower motor neuron findings, sensory ataxia) | Check methylmalonic acid and homocysteine if B12 is borderline (200-400 pg/mL) |
| Hemoglobin A1c | Screen for diabetes | Diabetes is the most common cause of peripheral neuropathy in developed countries | Also check fasting glucose; some patients have neuropathy at pre-diabetic levels |
Targeted Investigations by Suspected Localization
If Suspecting Upper Motor Neuron Lesion (Brain or Spinal Cord)
First-Line Tests
- MRI brain with and without contrast: Essential for stroke, tumor, demyelination, structural lesions
- MRI spine with and without contrast: For myelopathy; identifies compression, transverse myelitis, demyelinating lesions, tumor
- CT head (if MRI unavailable or contraindicated): For acute stroke evaluation; less sensitive for posterior fossa and spinal cord
Second-Line Tests
- Lumbar puncture: For multiple sclerosis (oligoclonal bands), infectious or inflammatory myelitis, Guillain-Barré syndrome (albuminocytologic dissociation), carcinomatous meningitis
- Visual evoked potentials: May reveal subclinical optic neuritis in multiple sclerosis
- CT or MR angiography: If vascular lesion suspected (stroke, spinal dural arteriovenous fistula)
If Suspecting Lower Motor Neuron Lesion (Anterior Horn Cell, Root, Nerve)
First-Line Tests
- Electromyography (EMG) and nerve conduction studies (NCS): Essential for localizing lesion (root, plexus, nerve); distinguishes axonal from demyelinating; detects active denervation; confirms clinical localization
- MRI spine: For radiculopathy, identifies disc herniation, foraminal stenosis, tumor, or infection affecting roots
Second-Line Tests
- Lumbar puncture: For Guillain-Barré syndrome (elevated protein, normal cells) and chronic inflammatory demyelinating polyneuropathy
- Genetic testing: For hereditary neuropathy (Charcot-Marie-Tooth) if family history or characteristic phenotype
- Antibody panels: Anti-ganglioside antibodies (GM1 for multifocal motor neuropathy, GQ1b for Miller Fisher syndrome)
- Nerve biopsy: Rarely needed; for vasculitic neuropathy, amyloidosis, or atypical inflammatory neuropathy
If Suspecting Neuromuscular Junction Disorder
First-Line Tests
- Acetylcholine receptor (AChR) antibodies: Positive in approximately 85% of generalized myasthenia gravis, approximately 50% of ocular myasthenia
- Muscle-specific kinase (MuSK) antibodies: Check if AChR negative; positive in approximately 40% of AChR-negative myasthenia gravis
- Repetitive nerve stimulation: Decremental response (greater than 10% decrement) at low-frequency stimulation (2-3 Hz) supports myasthenia gravis
- CT chest: To evaluate for thymoma (present in approximately 10-15% of myasthenia gravis patients)
Second-Line Tests
- Single-fiber EMG: Most sensitive test for neuromuscular junction disorders; increased jitter diagnostic
- Voltage-gated calcium channel (VGCC) antibodies: For Lambert-Eaton myasthenic syndrome
- Anti-LRP4 antibodies: Check if AChR and MuSK negative in suspected myasthenia
- Edrophonium (Tensilon) test: Rarely used now due to availability of antibody testing; transient improvement confirms neuromuscular junction disorder
If Suspecting Myopathy
First-Line Tests
- Creatine kinase (CK): Usually elevated (5-50 times normal in inflammatory myopathy); may be normal in steroid myopathy and some chronic myopathies
- Aldolase: May be elevated even when CK is normal; useful in antisynthetase syndrome
- Electromyography: Shows myopathic pattern (small, short, polyphasic motor unit potentials with early recruitment); distinguishes from neurogenic weakness
- Thyroid function tests: Both hypothyroidism and hyperthyroidism cause myopathy
Second-Line Tests
- Myositis-specific antibodies: Anti-Jo-1 (antisynthetase syndrome), anti-Mi-2 (dermatomyositis), anti-SRP and anti-HMGCR (necrotizing myopathy)
- MRI of affected muscles: Shows edema and inflammation in active myositis; guides biopsy site; fatty replacement in chronic myopathy
- Muscle biopsy: Definitive diagnosis; shows inflammation, necrosis, specific patterns for different myopathies
- Malignancy screening: CT chest/abdomen/pelvis in dermatomyositis and older patients with inflammatory myopathy (paraneoplastic association)
- Genetic testing: For suspected muscular dystrophy or metabolic myopathy
If Suspecting Motor Neuron Disease (Amyotrophic Lateral Sclerosis)
Diagnostic Studies
- EMG/NCS: Shows widespread denervation in multiple body regions (bulbar, cervical, thoracic, lumbosacral); fasciculations; normal sensory studies
- MRI brain and spine: Primarily to exclude structural mimics (cervical stenosis, tumor, syrinx); may show corticospinal tract signal changes
To Exclude Mimics
- Lumbar puncture: Normal in amyotrophic lateral sclerosis; excludes inflammatory conditions
- Anti-GM1 antibodies: Multifocal motor neuropathy is treatable mimic
- Genetic testing: SOD1 and C9orf72 in familial cases (approximately 10% of amyotrophic lateral sclerosis)
- Hexosaminidase A level: To exclude adult-onset Tay-Sachs (rare mimic)
Empiric Treatment Trials as Diagnostic Tools
When Empiric Trials May Help
In some cases, response to treatment can support a diagnosis when other tests are inconclusive:
- Pyridostigmine trial for suspected myasthenia gravis: Improvement in fatigable weakness after acetylcholinesterase inhibitor supports diagnosis, especially when antibodies are negative (seronegative myasthenia)
- Corticosteroid trial for suspected inflammatory myopathy: Improvement in strength and decline in creatine kinase over 4-8 weeks supports inflammatory etiology; lack of response should prompt reconsideration (consider inclusion body myositis)
- Intravenous immunoglobulin trial for suspected chronic inflammatory demyelinating polyneuropathy: Improvement in strength and function over 2-4 weeks strongly supports diagnosis and indicates treatability
- Thyroid hormone replacement: Resolution of weakness over weeks to months after treating hypothyroidism confirms thyroid myopathy
- Discontinuation of suspected offending medication: Improvement after stopping statin or other myotoxic drug supports drug-induced cause (though immune-mediated necrotizing myopathy may not resolve)
Urgent Investigations: When Time Matters
Do Not Delay These Investigations
- Suspected stroke: CT head immediately; consider CT angiography and perfusion imaging for thrombectomy eligibility
- Suspected spinal cord compression: MRI whole spine with contrast urgently (within hours, not days)
- Suspected Guillain-Barré syndrome: Admit for monitoring; lumbar puncture and nerve conduction studies within 24-48 hours; serial forced vital capacity measurements
- Suspected myasthenic crisis: Arterial blood gas, forced vital capacity; admit to ICU if respiratory compromise
- Severe hypokalemia (less than 2.5 mEq/L): ECG immediately; cardiac monitoring; urgent replacement
- Suspected botulism: Stool and serum for toxin; contact public health; antitoxin administration
Investigation Summary by Clinical Presentation
| Clinical Presentation | First-Line Investigations | Key Findings to Expect |
|---|---|---|
| Sudden focal weakness | CT head (immediate), MRI brain, vascular imaging | Infarct or hemorrhage on imaging |
| Ascending weakness with areflexia | Lumbar puncture, EMG/NCS, forced vital capacity | Elevated CSF protein with normal cells; demyelinating pattern on NCS |
| Fatigable weakness with ptosis | AChR antibodies, repetitive nerve stimulation, CT chest | Positive antibodies; decremental response on RNS; possible thymoma |
| Proximal weakness with elevated CK | Myositis antibodies, EMG, MRI muscle, consider biopsy | Myopathic EMG; muscle edema on MRI; inflammatory infiltrate on biopsy |
| Weakness with upper and lower motor neuron signs | EMG/NCS (extensive), MRI brain and spine | Widespread denervation; exclusion of structural disease |
| Distal weakness with sensory loss | EMG/NCS, glucose, B12, consider LP if demyelinating | Axonal or demyelinating pattern; identifies underlying cause |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for weakness
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Sudden onset hemiparesis (minutes to hours) | EMERGENT | Activate stroke protocol; CT head immediately; consider thrombolysis if within window; neurology consultation |
| Rapidly ascending weakness with respiratory compromise | EMERGENT | ICU admission; monitor forced vital capacity every 2-4 hours; prepare for intubation if FVC less than 20 mL/kg or declining greater than 30% |
| Weakness below a spinal level with bowel/bladder dysfunction | EMERGENT | MRI whole spine urgently; dexamethasone if malignant compression suspected; emergent surgical or oncology consultation |
| Severe bulbar weakness with aspiration risk | EMERGENT | NPO status; aspiration precautions; consider NG tube; evaluate for myasthenic crisis or bulbar amyotrophic lateral sclerosis |
| Weakness with severe hypokalemia (less than 2.5 mEq/L) | EMERGENT | Continuous cardiac monitoring; ECG; intravenous potassium replacement; identify cause |
| Descending paralysis with pupillary changes (suspected botulism) | EMERGENT | Contact public health; obtain antitoxin; ICU monitoring; respiratory support |
| Progressive weakness over days with areflexia | URGENT | Admit for observation; serial respiratory assessments; lumbar puncture and EMG/NCS within 24-48 hours; consider Guillain-Barré syndrome |
| New fatigable weakness with ptosis and diplopia | URGENT | Assess for respiratory and bulbar involvement; acetylcholine receptor antibodies; CT chest for thymoma; neurology referral within days |
| Proximal weakness with very elevated creatine kinase (greater than 10,000 U/L) | URGENT | Aggressive hydration; monitor renal function and urine output; evaluate for rhabdomyolysis; stop potential offending medications |
| Slowly progressive weakness over months without red flags | ROUTINE | Outpatient workup; baseline laboratories; EMG/NCS; neurology referral within weeks |
| Generalized fatigue without objective weakness | ROUTINE | Screen for depression, sleep disorders, anemia, thyroid disease; address as fatigue rather than neurological weakness |
Step 2: Classify by Duration and Onset
Hyperacute (seconds to minutes)
Think vascular first
Proceed to Stroke Algorithm
CT head → Consider thrombolysis → MRI → Vascular imaging
Acute (hours to days)
Think inflammatory/toxic
Proceed to Acute Weakness Algorithm
Electrolytes → Respiratory monitoring → LP and EMG → Immunotherapy consideration
Subacute to Chronic (weeks to months)
Think degenerative/metabolic/structural
Proceed to Progressive Weakness Algorithm
Baseline labs → CK → EMG/NCS → Imaging → Consider biopsy
Step 3: Follow the Appropriate Algorithm
Algorithm A: Hyperacute Weakness (Stroke Suspected)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Sudden hemiparesis, onset less than 4.5 hours ago, no hemorrhage on CT | Acute ischemic stroke | Evaluate for IV thrombolysis (alteplase or tenecteplase); consider mechanical thrombectomy if large vessel occlusion |
| Sudden hemiparesis with hemorrhage on CT | Hemorrhagic stroke | Blood pressure control; reverse anticoagulation if applicable; neurosurgery consultation |
| Transient weakness resolved completely | Transient ischemic attack | Urgent stroke workup (carotid imaging, echocardiogram, risk stratification); antiplatelet therapy; admit or rapid outpatient evaluation |
| Weakness with seizure at onset | Seizure with Todd paralysis or stroke with seizure | Imaging to differentiate; if Todd paralysis, weakness should resolve within 24-48 hours; antiepileptic if seizure confirmed |
Algorithm B: Acute Weakness (Hours to Days)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Ascending weakness, areflexia, recent infection | Guillain-Barré syndrome | Admit; monitor FVC; lumbar puncture (elevated protein, normal cells); EMG/NCS; start IVIG or plasmapheresis if progressing |
| Generalized weakness with severe hypokalemia | Hypokalemic paralysis | Cardiac monitoring; IV potassium replacement; identify cause (diuretics, renal tubular acidosis, hyperaldosteronism, periodic paralysis) |
| Weakness below a level with back pain | Spinal cord compression or transverse myelitis | Emergent MRI spine; if compression, urgent decompression; if myelitis, lumbar puncture and IV corticosteroids |
| Worsening weakness in known myasthenia gravis patient | Myasthenic crisis | ICU admission; hold cholinesterase inhibitors initially; IVIG or plasmapheresis; treat trigger (infection common) |
| Descending weakness starting with cranial nerves | Botulism | Stool and serum toxin assay; contact public health; administer antitoxin; supportive care |
| Weakness in ICU patient, difficulty weaning from ventilator | Critical illness myopathy or polyneuropathy | EMG/NCS; minimize corticosteroids and neuromuscular blockers; aggressive rehabilitation; may take weeks to months to recover |
Algorithm C: Subacute and Chronic Progressive Weakness
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Proximal weakness, elevated CK, skin rash | Dermatomyositis | Myositis antibodies; MRI muscle; muscle biopsy; malignancy screening (CT chest/abdomen/pelvis); start corticosteroids |
| Proximal weakness, elevated CK, no rash | Polymyositis or immune-mediated necrotizing myopathy | Myositis antibodies (including anti-HMGCR and anti-SRP); biopsy; corticosteroids; if necrotizing myopathy, may need additional immunosuppression |
| Fatigable weakness, ptosis, diplopia | Myasthenia gravis | AChR and MuSK antibodies; repetitive nerve stimulation; CT chest; start pyridostigmine; consider immunosuppression |
| Mixed upper and lower motor neuron signs, fasciculations, no sensory loss | Amyotrophic lateral sclerosis | Comprehensive EMG/NCS; MRI to exclude structural disease; multidisciplinary care; discuss prognosis; riluzole |
| Proximal and distal weakness, areflexia, elevated CSF protein | Chronic inflammatory demyelinating polyneuropathy | EMG/NCS (demyelinating pattern); lumbar puncture; trial of IVIG or corticosteroids; dramatic response expected |
| Distal weakness with sensory loss in diabetic patient | Diabetic polyneuropathy | EMG/NCS; optimize glycemic control; evaluate for other contributing causes (B12, alcohol); symptomatic management of neuropathic pain |
| Proximal weakness on chronic corticosteroids | Steroid myopathy | CK usually normal; EMG may show myopathic changes; taper steroids if possible; physical therapy |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient on statin develops muscle weakness | Check CK; stop statin immediately | If CK very high, hydrate and monitor renal function; if weakness persists after 4-6 weeks, check anti-HMGCR antibodies for immune-mediated necrotizing myopathy |
| Antibody-negative suspected myasthenia gravis | Check MuSK antibodies; perform single-fiber EMG | Consider trial of pyridostigmine; if clinical response, treat as seronegative myasthenia; check anti-LRP4 if available |
| Inflammatory myopathy not responding to steroids | Reconsider diagnosis; ensure adequate dose and duration | Repeat biopsy if possible; consider inclusion body myositis (poor steroid response); add steroid-sparing agent (methotrexate, azathioprine, IVIG) |
| Patient with Guillain-Barré syndrome not improving after IVIG | Assess for complications (infection, deep vein thrombosis, dysautonomia) | Consider second course of IVIG or switch to plasmapheresis; recovery may take months; aggressive rehabilitation |
| Suspected amyotrophic lateral sclerosis but diagnosis uncertain | Do not give definitive diagnosis prematurely | Repeat EMG in 3-6 months; ensure all mimics excluded (cervical stenosis, multifocal motor neuropathy); El Escorial criteria require progression over time |
| Weakness with normal examination and normal initial workup | Reassess whether this is true weakness or fatigue | Screen for depression, sleep disorders, chronic fatigue syndrome; consider functional neurological disorder if examination inconsistencies present |
| Older patient with dermatomyositis | High suspicion for occult malignancy | CT chest, abdomen, pelvis; age-appropriate cancer screening; PET scan if available; repeat screening annually for 3 years |
Troubleshooting Refractory or Unexplained Weakness
When Weakness Persists Despite Workup, Ask These Questions
- Is this truly weakness? Re-examine to distinguish from fatigue, pain-limited effort, or functional disorder
- Is the localization correct? Review examination for upper versus lower motor neuron versus myopathy versus neuromuscular junction
- Were the right tests ordered? EMG/NCS interpretation is operator-dependent; consider repeat at specialized center
- Was sampling adequate? Patchy diseases (vasculitis, inclusion body myositis) may require targeted biopsy or repeat sampling
- Is there more than one process? Patients can have overlapping conditions (e.g., diabetic neuropathy plus vitamin B12 deficiency)
- Has enough time passed? Some conditions (e.g., amyotrophic lateral sclerosis) require observation over time to meet diagnostic criteria
- Have rare diagnoses been considered? Adult-onset spinal muscular atrophy, Kennedy disease, mitochondrial myopathy, metabolic myopathies
- Is malignancy being missed? Paraneoplastic syndromes can precede detectable cancer; repeat screening may be needed
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Clarify “weakness” first: Many patients use “weakness” to describe fatigue, malaise, or functional limitation. Always ask “Can you not do something, or do you feel tired?” This single question directs the entire workup.
Localization determines everything: The pattern of weakness, reflexes, tone, and sensory findings localize the lesion. Upper motor neuron, lower motor neuron, neuromuscular junction, and myopathy each have distinct presentations and completely different differentials.
Reflexes are your best friend: Hyperreflexia with Babinski sign points to upper motor neuron lesion. Areflexia points to lower motor neuron or Guillain-Barré syndrome. Preserved reflexes with weakness suggest neuromuscular junction or early myopathy.
The “20/30/40 rule” for Guillain-Barré syndrome: Consider intubation when forced vital capacity is less than 20 mL/kg, negative inspiratory force is weaker than -30 cm H2O, or there is greater than 30% decline in either. Do not wait for hypoxia.
Myasthenia gravis hides in plain sight: Fatigable ptosis, diplopia that varies throughout the day, and difficulty chewing at the end of meals are classic. The ice pack test (improvement in ptosis after 2 minutes of ice) is a free bedside diagnostic tool.
Upper and lower motor neuron signs together = amyotrophic lateral sclerosis until proven otherwise: Fasciculations with brisk reflexes is the hallmark combination. The “split hand” sign (preferential thenar wasting) is relatively specific and often present early.
Normal CK does not exclude myopathy: Steroid myopathy typically has normal CK. Chronic myopathies may have only mildly elevated or normal CK. EMG and muscle biopsy may be needed.
Dermatomyositis demands malignancy screening: Up to 25% of adult dermatomyositis patients have an underlying malignancy. Screen at diagnosis and repeat annually for at least 3 years. The malignancy may not be evident initially.
Critical Pitfalls to Avoid
Missing the respiratory emergency: Patients with Guillain-Barré syndrome and myasthenic crisis can deteriorate rapidly. A patient who “looks fine” may have critically reduced vital capacity. Monitor respiratory function serially in any patient with generalized neuromuscular weakness.
Assuming weakness is “just anxiety” or “functional”: While functional neurological disorders exist, this should be a diagnosis of positive identification (specific examination findings), not exclusion. Missed myasthenia gravis and early motor neuron disease have devastating consequences.
Forgetting medication-induced causes: Statins are ubiquitous and statin myopathy is common. Always ask about statins, steroids, and recent medication changes. Immune-mediated necrotizing myopathy can persist or progress even after stopping the statin.
Delaying spinal cord imaging: Spinal cord compression is a surgical emergency. Back pain with weakness below a level and sphincter dysfunction demands same-day MRI. Every hour of delay worsens prognosis.
Checking CK after EMG: Needle EMG causes muscle fiber injury and elevates CK for days. Always draw CK before the EMG to get an accurate baseline.
Giving fluoroquinolones to myasthenia gravis patients: Fluoroquinolones can precipitate myasthenic crisis. They are relatively contraindicated. If an antibiotic is needed, choose an alternative.
Diagnosing amyotrophic lateral sclerosis too quickly: Amyotrophic lateral sclerosis is devastating and irreversible. Ensure all mimics are excluded (cervical myelopathy, multifocal motor neuropathy, Kennedy disease). Observation over time is often necessary before confirming the diagnosis.
Overlooking Lambert-Eaton myasthenic syndrome: Unlike myasthenia gravis, Lambert-Eaton causes proximal weakness that improves briefly with exercise. It is strongly associated with small cell lung cancer. Always check voltage-gated calcium channel antibodies and image the chest.
Key Takeaways
- True weakness versus fatigue is the critical first distinction. True weakness means inability to perform a task; fatigue means exhaustion or lack of energy. This determines whether you pursue a neurological or systemic workup.
- Localization is the foundation of diagnosis. Determine whether the lesion is upper motor neuron, lower motor neuron, neuromuscular junction, or muscle based on the pattern of weakness, reflexes, tone, and sensory findings.
- Acute weakness can be life-threatening. Stroke, Guillain-Barré syndrome, myasthenic crisis, and spinal cord compression are emergencies. Recognize them early and act immediately.
- Monitor respiratory function in all neuromuscular weakness. Do not rely on oxygen saturation alone. Serial measurement of forced vital capacity and negative inspiratory force guides timing of intubation.
- Medication review is essential. Statins, corticosteroids, and many other drugs cause weakness. Always ask about medications, and do not forget over-the-counter supplements and alcohol.
- A normal examination does not exclude serious disease. Myasthenia gravis, early motor neuron disease, and metabolic myopathies can have subtle or fluctuating findings. If the history is convincing, pursue further testing.
- EMG and nerve conduction studies are the workhorse investigations. They distinguish neurogenic from myopathic weakness, identify demyelinating versus axonal processes, and guide further testing including biopsy.
- Think about malignancy in inflammatory myopathy. Dermatomyositis and polymyositis in adults require malignancy screening. Lambert-Eaton myasthenic syndrome is a paraneoplastic syndrome until proven otherwise.
- Treatment can be diagnostic. Response to pyridostigmine supports myasthenia gravis. Response to IVIG supports chronic inflammatory demyelinating polyneuropathy. Lack of response to steroids should prompt reconsideration of the diagnosis.
- Multidisciplinary care improves outcomes. Patients with chronic neuromuscular weakness benefit from neurology, physical therapy, occupational therapy, speech therapy, respiratory therapy, and often palliative care involvement.
Quick Reference Algorithm
Systematic Approach to Weakness:
- Clarify the complaint: Is this true weakness or fatigue? Can the patient not do something, or are they exhausted?
- Assess urgency: Are there red flags (sudden onset, respiratory compromise, bulbar symptoms, sphincter dysfunction)? If yes, act immediately.
- Localize the lesion: Upper motor neuron, lower motor neuron, neuromuscular junction, or muscle? Use examination findings to determine level.
- Characterize the tempo: Hyperacute (vascular), acute (inflammatory/toxic), subacute (inflammatory/metabolic), or chronic (degenerative/hereditary)?
- Obtain baseline investigations: Complete blood count, comprehensive metabolic panel, creatine kinase, thyroid-stimulating hormone, vitamin B12 for all patients.
- Order targeted investigations: Based on localization — imaging for upper motor neuron lesions, EMG/NCS for lower motor neuron and myopathy, antibodies for neuromuscular junction disorders.
- Review medications: Stop potential offending agents (statins, steroids) and observe for improvement.
- Consider empiric treatment trials: When diagnosis is uncertain, response to therapy can be diagnostic (pyridostigmine, IVIG, corticosteroids).
- Reassess and reconsider: If the patient is not improving as expected, revisit the localization, consider alternative diagnoses, and repeat key tests.
- Engage the team: Neurology, physical therapy, occupational therapy, and other specialists as needed for comprehensive management.